Monitoring of treatment with biological drugs

Promonitor  ProteomikaPROMONITOR is an ELISA test designed for the monitoring of patients treated with biological therapy.

PROMONITOR is a double test that allows:

  • The quantitative determination of drug plasma levels.
  • The quantitative determination of antibodies produced against the biological drug.

The analysis of these parameters offers a high predictive power on the evolution and clinical response of the patient.

PRODUCTS

  • GLM Promonitor (Levels of Golimumab)
  • Promonitor IFX (Levels of Infliximab)
  • Promonitor ADL (Levels of Adalimumab)
  • Promonitor ETN (Etanercept Levels)
  • Promonitor RTX (Levels of Rituximab)
  • Promonitor VDZ (Levels of Vedolizumab)
  • Promonitor Anti-GLM (Anti-Golimumab Antibodies)
  • Promonitor Anti-IFX (Anti-Infliximab Antibodies)
  • Promonitor Anti-ADL (Anti-Adalimumab Antibodies)
  • Promonitor Anti - ETN (Anti-Etanercept Antibodies)
  • Promonitor Anti-RTX (Anti-Rituximab Antibodies)
  • Promonitor Anti-VDZ (Anti-Vedolizumab Antibodies)

Literature

Please feel free to download the following literature published on promonitor.

Guidelines 

Therapeutical Cut-offs and guidelines


ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS

Poster presentation (RA):

Monitoring of anti-TNF biological treatments - discussion

 

Scientific publications (RA):


treatment of spondyloarthritis with infl iximab
treatment of spondyloarthritis with infl iximab

ACCESS TO INNOVATIVE TREATMENTS IN RHEUMATOID ARTHRITIS IN EUROPE

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

EVALUATION OF ANTI-TNF LEVELS AND ANTI-TNF ANTIBODIES IN RHEUMATIC DISEASES TREATED WITH INFLIXIMAB AND ADALIMUMAB; RESULTS FROM A LOCAL REGISTRY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Social and Personal Costs of Arthritis and Rheumatic Diseases: An Exploratory Survey Undertaken for the Nordic Rheuma Council (NRR)

Development of Antiinfliximab Antibodies and Relationship to Clinical Response in Patients With Rheumatoid Arthritis

Dealing with immunogenicity of biologicals: assessment and clinical relevance

 

Scientific publications (bowel disease):

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokineticsand immunogenicity of anti-tumour necrosis factor-alpha antibodies

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease

Copyright © Biocom Diagnostics